- Home
- GH vs SF Comparison
GH vs SF Comparison
Compare GH & SF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GH | SF |
|---|---|---|
| Founded | 2011 | 1890 |
| Country | United States | United States |
| Employees | N/A | 9000 |
| Industry | Medical Specialities | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.7B | 11.4B |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | GH | SF |
|---|---|---|
| Price | $118.94 | $72.60 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 19 | 7 |
| Target Price | ★ $119.79 | $90.33 |
| AVG Volume (30 Days) | ★ 1.9M | 1.2M |
| Earning Date | 05-07-2026 | 04-22-2026 |
| Dividend Yield | N/A | ★ 1.76% |
| EPS Growth | ★ 6.74 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $982,021,000.00 | N/A |
| Revenue This Year | $33.30 | $14.58 |
| Revenue Next Year | $28.27 | $8.03 |
| P/E Ratio | ★ N/A | $20.53 |
| Revenue Growth | ★ 32.88 | N/A |
| 52 Week Low | $37.73 | $69.31 |
| 52 Week High | $121.01 | $134.74 |
Technical Indicators
Market Signals| Indicator | GH | SF |
|---|---|---|
| Relative Strength Index (RSI) | 77.61 | 35.70 |
| Support Level | $97.16 | $69.31 |
| Resistance Level | N/A | $74.07 |
| Average True Range (ATR) | 5.99 | 1.87 |
| MACD | 2.78 | -0.25 |
| Stochastic Oscillator | 94.08 | 14.22 |
Price Performance
Historical ComparisonAbout GH Guardant Health Inc.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
About SF Stifel Financial Corporation
Stifel Financial is a diversified financial-services provider that generates revenue from wealth management, investment banking, and lending. The firm was founded in 1890 as a St. Louis-based full-service brokerage but has been transformed under CEO Ronald Kruszewski through a slew of acquisitions into a globally competitive wealth manager, investment bank, and retail and institutional brokerage. The firm generated $5.5 billion in revenue in 2025, with roughly two-thirds derived from wealth management and one-third derived from investment banking and trading.